Editorial: RANKL links arterial calcification with osteolysis

Circulation Research

Volumn 104, Issue 9, 2009, Pages 1032-1034

  Alexander, M Yvonne ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

BMP4; OPG; RANKL; Vascular calcification

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; DENOSUMAB; I KAPPA B KINASE ALPHA; IBANDRONIC ACID; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; WARFARIN; BONE MORPHOGENETIC PROTEIN 4; OSTEOPROTEGERIN; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B;

ARTERY CALCIFICATION; BONE REMODELING; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG TARGETING; EDITORIAL; HUMAN; KIDNEY FAILURE; MORTALITY; NONHUMAN; OSSIFICATION; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; ANIMAL; CALCINOSIS; GENETICS; METABOLISM; NOTE; PATHOLOGY; PATHOPHYSIOLOGY; RAT; VASCULAR DISEASE; VASCULAR SMOOTH MUSCLE;

ANIMALS; BONE MORPHOGENETIC PROTEIN 4; BONE REMODELING; CALCINOSIS; HUMANS; MUSCLE, SMOOTH, VASCULAR; OSTEOLYSIS; OSTEOPROTEGERIN; RANK LIGAND; RATS; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR-KAPPA B; SIGNAL TRANSDUCTION; VASCULAR DISEASES;

EID: 66149102000     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.109.198010     Document Type: Editorial

References (25)

1. Neven E, Dauwe S, De Broe ME, D'Haese PC, Persy V. Endochondral bone formation is involved in media calcification in rats and in men. Kidney Int. 2007;72:574-581.
2. Proudfoot D, Davies JD, Skepper JN, Weissberg PL, Shanahan CM. Acetylated low-density lipoprotein stimulates human vascular smooth muscle cell calcification by promoting osteoblastic differentiation and inhibiting phagocytosis. Circulation. 2002;106:3044-3050.
3. Kirton JP, Wilkinson FL, Canfield AE, Alexander MY. Dexamethasone downregulates calcification-inhibitor molecules and accelerates osteogenic differentiation of vascular pericytes: implications for vascular calcification. Circ Res. 2006;98:1264-1272.
4. El-Abbadi M, Giachelli CM. Mechanisms of vascular calcification. Adv Chronic Kidney Dis. 2007;14:54-66.
5. Abedin M, Tintut Y, Demer LL. Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol. 2004;24: 1161-1170.
6. Budoff MJ, Shaw LJ, Liu ST, Weinstein SR, Mosler TP, Tseng PH, Flores FR, Callister TQ, Raggi P, Berman DS. Long-term prognosis associated with coronary calcification: observations from a registry of 25,253 patients. J Am Coll Cardiol. 2007;49:1860-1870.
7. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature. 2003;423:337-342.
8. Schoppet M, Preissner KT, Hofbauer LC. RANK ligand and osteopro-tegerin: paracrine regulators of bone metabolism and vascular function. Arterioscler Thromb Vasc Biol. 2002;22:549-553.
9. Tintut Y, Demer L. Role of osteoprotegerin and its ligands and competing receptors in atherosclerotic calcification. J Invest Med. 2006;54:395-401.
10. Bucay N, Sarosi I, Dunstan CR, Morony S, Tarpley J, Capparelli C, Scully S, Tan HL, Xu WL, Lacey DL, Boyle WJ, Simonet WS. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev. 1998;12:1260-1268.
11. Min H, Morony S, Sarosi I, Dunstan CR, Capparelli C, Scully S, Van G, Kaufman S, Kostenuik PJ, Lacey DL, Boyle WJ, Simonet WS. Osteo-protegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling oste-oclastogenesis. J Exp Med. 2000;192:463-474.
12. El-Maadawy S, Kaartinen MT, Schinke T, Murshed M, Karsenty G, McKee MD. Cartilage formation and calcification in arteries of mice lacking matrix Gla protein. Connect Tissue Res. 2003;44(suppl 1): 272-278.
13. Rutsch FM, Terkeltaub RM. Parallels between arterial and cartilage calcification: what understanding artery calcification can teach us about chondrocalcinosis. Curr Opin Rheumatol. 2003;15:302-310.
14. Shao JS, Cheng SL, Pingsterhaus JM, Charlton-Kachigian N, Loewy AP, Towler DA. Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals. J Clin Invest. 2005;115:1210-1220.
15. Tintut Y, Alfonso Z, Saini T, Radcliff K, Watson K, Bostrom K, Demer LL. Multilineage potential of cells from the artery wall. Circulation. 2003;108:2505-2510.
16. Johnson RC, Leopold JA, Loscalzo J. Vascular calcification: pathobio-logical mechanisms and clinical implications. Circ Res. 2006;99: 1044-1059.
17. Hozumi A, Osaki M, Goto H, Sakamoto K, Inokuchi S, Shindo H. Bone marrow adipocytes support dexamethasone-induced osteoclast differentiation. Biochem Biophys Res Commun. 2009;382:780-784.
18. Collin-Osdoby P. Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin. Circ Res. 2004;95: 1046-1057.
19. Panizo S, Cardus A, Encinas M, Parisi E, Valcheva P, López-Ongil S, Coll B, Fernandez E, Valdivielso JM. RANKL increases vascular smooth muscle cell calcification through a RANK-BMP4-dependent pathway. Circ Res. 2009;104:1041-1048.
20. Leboy PS. Regulating bone growth and development with bone morpho-genetic proteins. Ann N Y Acad Sci. 2006;1068:14-18.
21. Bostrom K, Watson KE, Horn S, Wortham C, Herman I, Demer LL. Bone morphogenetic protein expression in human atherosclerotic lesions. J Clin Invest. 1993;91:1800-1809.
22. Hruska KA, Mathew S, Saab G. Bone morphogenetic proteins in vascular calcification. Circ Res. 2005;97:105-114.
23. Price PA, Faus SA, Williamson MK. Bisphosphonates alendronate and ibandronate inhibit artery calcification at doses comparable to those that inhibit bone resorption. Arterioscler Thromb Vasc Biol. 2001;21: 817-824.
24. McClung MR, Lewiecki EM, Cohen SB, Bolognese MA, Woodson GC, Moffett AH, Peacock M, Miller PD, Lederman SN, Chesnut CH, Lain D, Kivitz AJ, Holloway DL, Zhang C, Peterson MC, Bekker PJ. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med. 2006;354:821-831. (Pubitemid 43290920)
25. Kostenuik P, Nguyen H, McCabe J, Warmington K, Kurahara C, Sun N, Chen C, Li L, Cattley R, Van G, Scully S, Elliott R, Grisanti M, Morony S, Tan H, Asuncion F, Li X, Ominsky M, Stolina M, Dwyer D, Dougall W, Hawkins N, Boyle W, Simonet W, Sullivan J. Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases bone density in knock-in mice that express chimeric (Murine/ Human) RANKL. J Bone Miner Res. In press.